North Hollywood, CA, September 22, 2010 — According to an article posted on Sept. 3 in Infectious Disease News data was presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy showing the quadrivalent human papillomavirus vaccine (Gardasil) did not raise the risk for developing autoimmune conditions. The study was sponsored by Merck and conducted on behalf of the Gardasil Safety Team.
Meanwhile back at the FDA Department of Health and Human Services, a letter was issued to GlaxoSmithKline Biologicals on September 2, 2010, granting “your request to supplement your biologics license application for Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant (Cervarix), to add lymphadenopathy to the Adverse Reactions, Postmarketing Experience section of the full prescribing information.”
S.A.N.E. Vax.org is asking: “Which one is it boys?”
According to Wikipedia, “lymphadenopathy is a term meaning “disease of the lymph nodes.” It is, however, almost synonymously used with “swollen/enlarged lymph nodes. It could be due to infection, auto-immune disease, or malignancy. Autoimmune etiology includes sarcoidosis, systemic lupus erythematosus, and rheumatoid arthritis all giving a generalized lymphadenopathy.“
To date, over 300 events have been reported to the Vaccine Adverse Event Reporting System (VAERS) where the vaccine is HPV or HPV4 (Gardasil) and the symptom is lymphadenopathy.
Norma Erickson, President of S.A.N.E Vax, Inc., referred to the latest Merck funded study on autoimmune diseases as “an outrageous excuse for a scientific study. There are over 60 autoimmune disorders reported to VAERS and the 16 least likely to exhibit (even with Gardasil) were chosen with percentages compiled on only 11 of those – and they were probably randomly sampled.”
On another front – vaccine notables will be gathering at the University of Pennsylvania on Tuesday September 21, 2010 for a Bioethics Conference on The Science, Ethics and Politics of Vaccine Mandates.
Mandating HPV Vaccine will be the topic of an afternoon panel session with Merck Vaccines Senior Director, Health Policy; and representatives from GlaxoSmithKline- Public Policy & Advocacy-Vaccines Division; Columbia University Public Health, and the Children’s Hospital of Pennsylvania.
Diane Harper, MD – Univ. of Missouri-Kansas City School of Medicine, who contributed to the studies of Cervarix and Gardasil worldwide will also be participating in the panel presentation.
Dr. Harper stated in a 2009 Philadelphia Bulletin interview that the “controversial drugs will do little to reduce cervical cancer rates and, even though they’re being recommended for girls as young as nine, there have been no efficacy trials in children under the age of 15.”
Dr. Harper also believes that young girls and their parents should receive more complete warnings before receiving the (HPV) vaccine to prevent cervical cancer, and that the current vaccines should not be mandated.
Parents need to be aware of the sundry and unorthodox messages from pharmaceutical marketeers who influence public policy. Mixed messages, lack of credible information and motives for profit are a poor excuse for mandating any vaccine.